D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.
|Videos|April 3, 2012
Conference Coverage From the ATA Annual Meeting
Author(s)Onclive Team
Conferencd coverage from the 82nd Annual Meeting of the American Thyroid Association (ATA).
Advertisement
Live coverage from the 82nd Annual Meeting of the American Thyroid Association (ATA) from September 19-23, 2012, at the Hilton Quebec and Quebec City Convention Centre, Quebec City, PQ, Canada.
The meeting featured cutting-edge educational sessions, great networking opportunities, and unmatched collegiality.
Find out more at
Not signed up to receive OncLive emails? Make an account today to make sure you don't miss updates from our conference coverage.
Advertisement
Related to this article
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
2
Arlo-Cel Meets ORR End Point in BCMA-Pretreated, Quadruple-Class Exposed R/R Myeloma
3
Camidge and Singhi Highlight the Lung Cancer Abstracts to Watch at WCLC 2026
4
Frontline Mipletamig Triplet Drives Clinical Benefit in TP53-Mutated AML
5